Esperion Therapeutics Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (34)

Latest Posts

About This Stock More About This Stock
Esperion - Raising Prospects In Lowering Cholesterol
Article By: MoneyShow.com
Sunday, July 12, 2020 2:04 PM EDT
Esperion Therapeutics just announced a pooled efficacy analysis from the four Phase III clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine.
In this article: ESPR
Read
JMP Reiterates $191 Price Target On Esperion After Japan Partnership
Article By: The Fly
Monday, April 20, 2020 1:16 PM EDT
JMP Securities analyst Jason Butler reiterates an "Outperform" rating on Esperion Therapeutics, with a $191 price target after the company announced a Japanese partnership with Otsuka, for its bempedoic acid franchise.
In this article: ESPR, OTSKY
Read
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich
Friday, January 26, 2018 6:44 PM EDT
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
3 Of The Best & Worst Performing Drug Stocks Of Q1
Article By: Arpita Dutt
Thursday, April 6, 2017 11:37 AM EDT
Pharma and biotech stocks have been showing signs of recovery this year. The sector started the year on a strong note with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10.7% and 5.7%, in the first quarter of 2017.
In this article: ESPR, VRTX, NKTR, ARGS, CDTX, XENE
Read
Ruling By FDA Causes Shares Of Esperion Therapeutics, Inc. To Jump 50% Today
Article By: Lorimer Wilson
Monday, March 20, 2017 3:23 PM EDT
Esperion announced this morning that the FDA is willing to sign off on an approval for its lead drug - provided it clears LDL lowering goals in a pivotal study - without a cardio study as a prerequisite. Its shares soared more than 50% on the news.
In this article: AMGN, ESPR
Read

PARTNER HEADLINES

Latest Tweets for $ESPR

No tweets yet!